(lp0
S"Enanta: Half Cash, All Upside Seeking Alpha - Feb 28, 2017 Investors have likely been disappointed in the past year and three years, but the company's early stage pipeline could breathe new life into shares.Enanta Pharmaceuticals Inc.  Moves Lower on Volume Spike for February 28 - Equities.com"
p1
aS"Enanta Pharmaceuticals Inc. ENTA  Wall Street Journal - Mar 22, 2013 News Enanta Pharmaceuticals Inc.ENTA. Significant News Only. 02/27/17; Press Release. Enanta Announces CHMP Grants Positive Opinion for an Eight-Week Treatment Option with AbbVie's VIEKIRAX  +&nbsp;..."
p2
aS'Enanta Pharmaceuticals, Inc. Common Stock Quote &amp; Summary Data Nasdaq - Nov 8, 2012 We are a research and development-focused biotechnology company that uses our robust, chemistry-driven approach and drug discovery capabilities to create small molecule drugs primarily for the treatment of viral infections and liver diseases.'
p3
aS'Why Enanta Pharmaceuticals Inc. Shares Shot Higher Motley Fool - Dec 10, 2013 What: Shares of Enanta Pharmaceuticals , a small-molecule drug developer targeted at infectious disease, soared as much as 20% after clinical partner AbbVie  reported positive results from its second phase 3 trial of six&nbsp;...AbbVie oral hep C drugs cure 96 percent in late stage trial - Reuters'
p4
aS'A Fundamental Perspective On Enanta Pharmaceuticals Seeking Alpha - Nov 20, 2015 The FDA warning is related to the only approved drugs related to Enanta, thus makes this a very risky investment. Competition from GILD, JNJ and MRK is ... From my continuous market screening, one of the stocks that ticked the right boxes was Enanta ...'
p5
aS'Enanta Pharma  Announces Japanese MHLW Grants Priority Review for AbbVie ... StreetInsider.com - Mar 14, 2017 Enanta Pharmaceuticals, Inc. , a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that priority review has been granted by the&nbsp;...Enanta Announces Japanese Ministry of Health, Labour and Welfare Grants ... - Business Wire '
p6
aS'Enanta Pharmaceuticals Inc.  Moves Lower on Volume Spike for February 13 Equities.com - Feb 13, 2017 Enanta Pharmaceuticals Inc.  traded on unusually high volume on Feb. 13, as the stock lost 0.47% to close at $29.79. On the day, Enanta Pharmaceuticals Inc. saw 356,838 shares trade hands on 3,100 trades. Considering that the stock averages only&nbsp;...'
p7
aS'Enanta: Robust Balance Sheet With Numerous Catalysts Seeking Alpha - Oct 27, 2016 Enanta Pharmaceuticals  is a small-cap pharmaceutical company focused on liver diseases such as hepatitis C  and Nonalcoholic Steatohepatitis .'
p8
aS"Enanta Pharmaceuticals'  CEO Jay Luly on Q2 2016 Results - Earnings Call ... Seeking Alpha - May 9, 2016 Good afternoon, ladies and gentlemen. Welcome to the Enanta Pharmaceuticals Second Quarter Financial Results Conference Call."
p9
aS'Renaissance Technologies LLC Lowers Position in Enanta Pharmaceuticals Inc  BNB Daily  - Mar 10, 2017 Enanta Pharmaceuticals logo Renaissance Technologies LLC decreased its stake in shares of Enanta Pharmaceuticals Inc  by 18.1% during the fourth quarter, Holdings Channel reports.Enanta Pharmaceuticals, Inc.  EPS Projection At $-0.38 - Markets Daily'
p10
a.